Cytos has entered into an agreement with Pfizer to develop vaccines for a certain number of diseases based on the Swiss company's Immunodrug technology.

As part of the deal, Cytos will receive an upfront payment of 10 million Swiss francs ($9.1 million) and could receive up to 140 million francs ($127.5 million) in milestone and other payments.

Under the terms of the agreement, Pfizer will acquire the worldwide exclusive rights to market certain vaccines for specific disease targets, and will be responsible for the development, manufacturing and commercialization of the products. Cytos did not specify which disease targets are covered by the partnership, but spokesperson Claudine Blaser indicated that they "are not ones Cytos is developing in its own programme." The company currently has vaccine candidates for asthma and allergies, Alzheimer's disease, melanoma, hypertension, nicotine addiction and psoriasis.

Vontobel analyst Markus Metzger commented that "this is very important for Cytos because it's a validation of the technology on a broader base as a means of developing therapeutic vaccines, and it bodes well for the licensing of its other vaccines." Meanwhile, Martin Voegtli of Sal. Oppenheim suggested that Cytos will likely also enter into licence agreements for its hypertension and allergy vaccine candidates, adding that they "have clearly blockbuster potential."